Basel, Basel, Switzerland
Inspired to improve patients’ lives through innovation in vision care. I am a global R&D and portfolio leader aligning science, execution, and governance. Energized by collaboration, structure, and delivering results that matter.
Global strategic leadership role accountable for the early development and commercialization of new modalities in Ophthalmology and Hepatology. Leading multidisciplinary Global Drug Development Program Teams across pre-clinical research, translational medicine, clinical development, CMC, regulatory and commercial functions. Developing and executing cross functional development strategies from pre-clinical stages to registration while ensuring patient and market access. Responsible Novartis Development leader for LNP023 in early/intermediate AMD and FWY003 development in Geographic Atrophy Novartis Lead for MACUSTAR IMI2 Project aiming for development of novel clinical endpoints for clinical trials in patients with intermediate AMD with a regulatory and patient access intention.
Responsible for implementing and driving global cross-functional business operations for Chemical and Analytical Development across different geographies and legal entities Lead, drive and implement strategic organizational initiatives
Formulation expert & project manager Formulation development and technical life cycle management for soft gelatin capsule products in aligment with contracting companies Planning, organization and excecution of feasibility studies, pilot-, clinical- and stability batches under GMP Process optimization and reformulation of existing products as well as contribution to process transfers between manufacturing sites Process transfer into commercial manufacturing One direct report
Ph.D. Thesis “Mobility of ESR spin probes after epicutaneous application under special consideration of interactions between liposomes and skin” Supervisor: Prof. Dr. H.-H. Borchert
Chief of Staff Lead franchise portfolio strategy development & oversee program execution by actively partnering with Global Program Heads, Research (NIBR), Global Drug Development Line Functions and Commercial/GMA functions to maximize the portfolio value and deliver as per plan. Develop Franchise strategy in collaboration with Global Head Development franchise, Head of New Product, Therapeutic Area Heads and NIBR. Oversee Ophthalmology portfolio incl. Lucentis, Beovu, Xiidra, SAF312, ECF843, UNR844 and early programs Ophthalmology business lead for 31bln Alcon Spin-off (2019) and Gyroscope Therapeutics integration (2022)